Last reviewed · How we verify
LEO 80185 vehicle
LEO 80185 vehicle is a topical formulation designed to deliver active pharmaceutical ingredients to the skin.
LEO 80185 vehicle is a topical formulation designed to deliver active pharmaceutical ingredients to the skin. Used for Dermatological conditions (specific indication unknown).
At a glance
| Generic name | LEO 80185 vehicle |
|---|---|
| Sponsor | LEO Pharma |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
As a vehicle formulation, LEO 80185 serves as the inactive carrier system for topical drug delivery, optimizing penetration and retention of the active ingredient at the site of application. The specific mechanism depends on the active drug combined with this vehicle, which is not specified in the available information.
Approved indications
- Dermatological conditions (specific indication unknown)
Common side effects
Key clinical trials
- LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs) (PHASE3)
- Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris (PHASE3)
- Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris (PHASE2)
- Skin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LEO 80185 vehicle CI brief — competitive landscape report
- LEO 80185 vehicle updates RSS · CI watch RSS
- LEO Pharma portfolio CI